632 time point. The study was designed to determine the effects of antibody treatment, with possible therapeutic applications in mind. To understand the physiological aspects, it would be more appropriate to study RNA and protein expression under different loading conditions. In addition, μCT evaluation in a region including the primary spongiosa might not reflect con- ditions in which growth plates are closed. In summary, we found that the large anabolic effect of Scl-Ab on traumatized bone in young male rats can also be found in unloaded bone. Sclerostin inhibition could be a valuable thera- peutic option in settings where the bone is unloaded. How- ever, we were unable to find an interaction between Scl-Ab treatment and loading, suggesting that although sclerostin is expressed in the bone that is forming in response to metaphy- seal trauma, this expression is not more sensitive to unloading than expression anywhere else. FA planned the study together with PA, performed the experiment, did the statistical evaluation, and wrote the draft manuscript. HI developed the CT applications, performed the measurements and analysis, and assisted in writ- ing. XL and HK assisted in study design and manuscript preparation. PA con- ceived and planned the study together with FA, and assisted in analysis and writing. XL and HK are employes of Amgen. PA has served as a consultant to Amgen and Eli Lilly and Company, and has financial interest in bisphosphonate coat- ing of bone implants. The research was funded by Amgen and the Swedish Research Council (VR2009-6725). Agholme F, Li X, Isaksson H, Ke H Z, Aspenberg P. Sclerostin antibody treat- ment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010; 25 (11): 2412-8. Agholme F, Isaksson H, Kuhstoss S, Aspenberg P. The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone 2011 (In Press). Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10 (5): 537-43. Brunkow M E, Gardner J C, Van Ness J, Paeper B W, Kovacevich B R, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001; 68 (3): 577-89. Acta Orthopaedica 2011; 82 (5): 628–632 Chappard D, Chennebault A, Moreau M, Legrand E, Audran M, Basle M F. Texture analysis of X-ray radiographs is a more reliable descriptor of bone loss than mineral content in a rat model of localized disuse induced by the Clostridium botulinum toxin. Bone 2001; 28 (1): 72-9. Chen Y, Whetstone H C, Lin A C, Nadesan P, Wei Q, Poon R, et al. Beta- catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med 2007; 4 (7): e249. Galli C, Passeri G, Macaluso G M. Osteocytes and WNT: the mechanical control of bone formation. J Dent Res 2010; 89 (4): 331-43. Kim J B, Leucht P, Lam K, Luppen C, Ten Berge D, Nusse R, et al. Bone regeneration is regulated by wnt signaling. J Bone Miner Res 2007; 22 (12): 1913-23. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280 (20): 19883-7. Li X, Ominsky M S, Niu Q T, Sun N, Daugherty B, D’Agostin D, et al. Tar- geted deletion of the sclerostin gene in mice results in increased bone for- mation and bone strength. J Bone Miner Res 2008; 23 (6): 860-9. Li X, Ominsky M S, Warmington K S, Morony S, Gong J, Cao J, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24 (4): 578-88. Li X, Warmington K S, Niu Q T, Asuncion F J, Barrero M, Grisanti M, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010; 25 (12): 2371-80. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009; 24 (10): 1651-61. Ominsky M S, Vlasseros F, Jolette J, Smith S Y, Stouch B, Doellgast G, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010; 25 (5): 948-59. Ominsky M S, Li C, Li X, Tan H L, Lee E, Barrero M, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones. J Bone Miner Res 2011; 26 (5): 1012-21. Poole K E, van Bezooijen R L, Loveridge N, Hamersma H, Papapoulos S E, Lowik C W, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19 (13): 1842-4. Robling A G, Niziolek P J, Baldridge L A, Condon K W, Allen M R, Alam I, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008; 283 (9): 5866-75. Tian X, Jee W S, Li X, Paszty C, Ke H Z. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 2011; 48 (2): 197-201. Warner S E, Sanford D A, Becker B A, Bain S D, Srinivasan S, Gross T S. Botox induced muscle paralysis rapidly degrades bone. Bone 2006; 38 (2): 257-64.